Effect of valproic acid on functional bleb morphology in a rabbit model of minimally invasive surgery.
Yap Zhu Li, Seet Li-Fong, Chu Stephanie Wl, Toh Li Zhen, Ibrahim Farah Ilyana, Wong Tina T
AI Summary
Valproic acid improved bleb survival and morphology in a rabbit MIGS model by reducing scar tissue and promoting healthier collagen, suggesting a promising adjunctive therapy for glaucoma surgery.
Abstract
Purpose
To determine the effect of valproic acid (VPA) on bleb morphology and scar characteristics in a rabbit model of minimally invasive glaucoma surgery (MIGS).
Methods
Nine New Zealand white rabbits were subjected to MIGS with intraoperative implantation of the PreserFlo MicroShunt. Rabbits were then administered with subconjunctival injections of phosphate buffered saline (PBS) (n=4) or with VPA (n=5). Bleb morphology was examined by slit-lamp biomicroscopy and in vivo confocal microscopy. Postoperative day 28 tissues were examined by immunohistochemical evaluation and label-free multiphoton microscopy to visualise the collagen matrix, by terminal deoxynucleotidyl transferase dUTP nick-end labelling assay and immunofluorescent labelling for Ki67 expression to detect apoptosis and cell growth, and by real-time quantitative PCR to measure Col1a1 , Fn , and Smad6 transcript expression.
Results
VPA-treated blebs were detectable on day 28, while the PBS-treated blebs were not detectable by day 14. VPA-treated blebs were diffuse, extended posteriorly with near normal conjunctival vascularity and featured a combination of reticular/blurred stromal pattern with evidence of relatively large stromal cysts. Instead of the deposition of thick, disorganised collagen fibres characteristic of the PBS bleb, the VPA bleb contained conspicuously thinner collagen fibres which were associated with similarly thinner fibronectin fibres. In corroboration, Col1a1 and Fn mRNA expression was reduced in the VPA blebs, while increased Smad6 expression implicated the disruption of the transforming growth factor beta pathway. Apoptosis and cell growth profiles appeared similar with both treatments.
Conclusions
The results support the application of VPA to enhance bleb morphology associated with good bleb function in MIGS with no apparent cytotoxicity.
MeSH Terms
Shields Classification
Key Concepts5
Valproic acid (VPA) treated blebs were detectable on day 28 in a rabbit model of minimally invasive glaucoma surgery (MIGS) with intraoperative implantation of the PreserFlo MicroShunt, while phosphate buffered saline (PBS) treated blebs were not detectable by day 14.
Valproic acid (VPA) treated blebs were diffuse, extended posteriorly with near normal conjunctival vascularity and featured a combination of reticular/blurred stromal pattern with evidence of relatively large stromal cysts in a rabbit model of minimally invasive glaucoma surgery (MIGS) with intraoperative implantation of the PreserFlo MicroShunt.
Valproic acid (VPA) treated blebs contained conspicuously thinner collagen fibres and similarly thinner fibronectin fibres compared to the deposition of thick, disorganised collagen fibres characteristic of phosphate buffered saline (PBS) blebs in a rabbit model of minimally invasive glaucoma surgery (MIGS) with intraoperative implantation of the PreserFlo MicroShunt.
Col1a1 and Fn mRNA expression was reduced in valproic acid (VPA) treated blebs, while increased Smad6 expression implicated the disruption of the transforming growth factor beta pathway in a rabbit model of minimally invasive glaucoma surgery (MIGS) with intraoperative implantation of the PreserFlo MicroShunt.
The application of valproic acid (VPA) enhanced bleb morphology associated with good bleb function in minimally invasive glaucoma surgery (MIGS) with no apparent cytotoxicity in a rabbit model with intraoperative implantation of the PreserFlo MicroShunt.
Related Articles5
New treatments for glaucoma.
ReviewValproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery.
Basic SciencePreliminary antifibrotic and vasoconstrictor effects of adrenaline in Schlemm's canal and suprachoroidal minimally invasive glaucoma surgery in primary open-angle glaucoma.
Clinical TrialiStent inject trabecular micro-bypass stents with topical prostaglandin as standalone treatment for open-angle glaucoma: 4-year outcomes.
Clinical TrialIntraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.